Treatment options in metastatic renal carcinoma: An embarrassment of riches

被引：51

作者：

Vogelzang, NJ ^{[1
]}

机构：

[1] Univ Nevada, Sch Med, Las Vegas, NV 89154 USA

[2] Nevada Canc Inst, Las Vegas, NV USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 01期

关键词：

D O I：

10.1200/JCO.2005.03.7234

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1 / 3

页数：3

共 14 条

[1]

Escudier B, 2005, J CLIN ONCOL, V23, p380S, DOI 10.1200/jco.2005.23.16_suppl.lba4510

[2]

Hainsworth JD, 2004, J CLIN ONCOL, V22, p382S

[3]

Hainsworth JD, 2005, J CLIN ONCOL, V23, p388S

[4] Tyrosine kinases as targets for cancer therapy [J].

Krause, DS ;

Van Etten, RA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02) :172-187

[5]

Motzer RJ, 2004, J CLIN ONCOL, V22, p382S

[6]

Motzer RJ, 2005, J CLIN ONCOL, V23, p380S

[7] Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma [J].

Motzer, RJ ;

Michaelson, MD ;

Redman, BG ;

Hudes, GR ;

Wilding, G ;

Figlin, RA ;

Ginsberg, MS ;

Kim, ST ;

Baum, CM ;

DePrimo, SE ;

Li, JZ ;

Bello, CL ;

Theuer, CP ;

George, DJ ;

Rini, BI .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) :16-24

[8]

Ratain MJ, 2005, J CLIN ONCOL, V23, p388S

[9]

RATAIN MJ, 2004, J CLIN ONCOL, V22, P14

[10]

Rini B, 2005, J CLIN ONCOL, V23, p380S

← 1 2 →